Inclusion Criteria:

          -  Subjects with suspected brain tumors undergoing surgical removal as their standard of
             care will be eligible; these may include subjects' status post chemotherapy and/or
             radiation or subjects who have undergone diagnostic biopsy for their original
             diagnosis and are assessed to be candidates for resection

          -  Subjects must be eligible for resection as determined by the operating surgeon

          -  Platelet count ≥ 75,000/mm^3

        Exclusion Criteria:

          -  Received an investigational drug within 30 days prior to first dose of
             panitumumab-IRDye800

          -  Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive
             heart failure (CHF); significant liver disease; or unstable angina within 6 months
             prior to enrollment

          -  History of infusion reactions to monoclonal antibody therapies

          -  Pregnant or breastfeeding

          -  Evidence of corrected QT (QTc) prolongation on pre-treatment electrocardiography (ECG)
             (greater than 440ms in males or greater than 460ms in females)

          -  Thyroid-stimulating hormone (TSH) ≥ 13 micro international units/mL

          -  Magnesium, potassium and calcium < the lower limit of normal per institution normal
             lab values

          -  Other lab values that in the opinion of the primary surgeon would prevent surgical
             resection

          -  Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide,
             amiodarone, sotalol) antiarrhythmic agents

          -  Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis

          -  Subjects not deemed to be appropriate candidates for optimal resection of tumor based
             on location, involvement of eloquent brain, satellite lesions, or other factors not
             specifically listed here